Key clinical point: Nivolumab plus platinum/etoposide chemotherapy had acceptable toxicity and improved efficacy outcomes in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC), though the results may be insufficient to change clinical practice.
Major finding: Risks of progression and death were reduced by 32% and 27%, respectively, when the immune checkpoint inhibitor was given along with chemotherapy.
Study details: ECOG-ACRIN EA5161, a randomized phase 2 trial including 160 patients with previously untreated ES-SCLC.
Disclosures: The study was sponsored by the National Cancer Institute. The presenting author provided disclosures related to AbbVie, AstraZeneca, Bayer, BeyondSpring, Bristol-Myers Squibb, Genentech, InvisionFirst Lung, Merck, Mirati, Novocure, and Takeda.
Leal TA et al. ASCO 2020, Abstract 9000.